Sequence Bioinformatics

The page features Sequence Bio’s latest news, announcements, publications, and scientific presentations.

The population of Newfoundland and Labrador is largely descended from settlers who migrated mainly from England and Ireland in the 1700s and 1800s. Data on the population’s genetic ancestry remains fragmentary.

A study by RCSI University of Medicine and Health Sciences and Sequence Bio provides a detailed genetic analysis of people in Newfoundland and Labrador, describing a founder population structure for studying health-related genetic variants.

Sequence Bio entered into a research collaboration agreement with Memorial University for its Study of Familial Multiple Sclerosis.

Sequence Bio has updated its brand to reflect how its work has evolved and its goal of discovering the future of medicine.

Sequence Bio entered into a three-year collaboration agreement with LEO Pharma to use its discovery platform to identify dermatologic drug targets. Sequence Bio will analyze samples from discovery cohorts across multiple dermatologic indications.

The company is building a team and has open positions.

The company combines expertise in genetics, translational biology, and research ethics with a commitment to patients.

The company has research opportunities, R&D partnerships, and job openings.

The company studies the genetic causes of inherited disease to support drug discovery with targets and predictors of drug response.

The page explains how information is collected, used, and managed when visitors access the website.

GitHubRepository owner

Sequence Bio enters a three-year, multi-indication discovery collaboration with LEO Pharma. The collaboration uses multi-omic analyses of powered discovery cohorts to identify novel dermatologic drug targets.

Apr 2022 · PR NewswireNews article

Sequence Bio began recruiting 2,500 volunteers for its Newfoundland genome project, seeking genetic and medical data to identify drug targets. Ethicists raised concerns about data control, and the project followed court battles with the provincial research ethics board.

Jul 2019 · CBC NewsNews article

A Newfoundland and Labrador Supreme Court judge ruled in Sequence Bio’s favor, directing the provincial Health Research Ethics Board to consider and decide research applications within 30 days. The ruling followed a nearly seven-month delay in deciding the company’s genome project application.

Feb 2019 · CBC NewsNews article